20 July 2023quarterly activities report● Neutral
Arcadia Biosciences, Inc. reported quarterly revenue of $1.3 million and net income of $823 thousand for the period ended 2023-06-30.
Announcements, explained
Each one in plain English, with the numbers worked through for a shareholder.
16 June 2023director interest notice● Neutral
Arcadia Biosciences, Inc. director Albert D. Bolles received a stock option grant for 937 shares.
16 June 2023director interest notice● Neutral
Arcadia Biosciences, Inc. director Deborah D Carosella received a stock option grant for 937 shares.
16 June 2023director interest notice● Neutral
Arcadia Biosciences, Inc. director Gregory D Waller received a stock option grant for 937 shares.
16 June 2023director interest notice● Neutral
Arcadia Biosciences, Inc. director Kevin Comcowich received a stock option grant for 2,186 shares.
16 June 2023director interest notice● Neutral
Arcadia Biosciences, Inc. director Lilian Shackelford Murray received a stock option grant for 937 shares.
16 June 2023director interest notice● Neutral
Arcadia Biosciences, Inc. director Amy Yoder received a stock option grant for 937 shares.
30 May 2023director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Executive Officer Stanley Jacot Jr. bought 5,000 shares on the open market at $4.31.
15 May 2023quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $1.2 million and a net loss of $9.4 million for the period ended 2023-03-31.
11 May 2023quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $1.2 million and a net loss of $9.4 million for the period ended 2023-03-31.
28 Apr 2023director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Financial Officer Thomas J. Schaefer received a stock option grant for 1,500 shares.
28 Apr 2023director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Marketing Officer Laura Pitlik received a stock option grant for 1,500 shares.
28 Apr 2023director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Executive Officer Stanley Jacot Jr. received a stock option grant for 1,500 shares.
18 Apr 2023securities registration● Neutral
Arcadia Biosciences, Inc. filed the final prospectus for a registered offering.
3 Apr 2023securities registration● Neutral
Arcadia Biosciences, Inc. registered a securities offering with the SEC using its shelf eligibility.
3 Mar 2023securities registration● Neutral
Arcadia Biosciences, Inc. filed the final prospectus for a registered offering.
3 Mar 2023capital raising announcement▲ GoodMajor
Arcadia raised capital in a private placement at $9.00/share (666,334 shares or pre-funded warrants) plus Series A and Series B investment options -- pricing consistent with a reverse stock split having taken effect since the 2022 sub-$1 financings.
3 Mar 2023securities registration● Neutral
Arcadia Biosciences, Inc. filed the final prospectus for a registered offering.
3 Mar 2023securities registration● Neutral
Arcadia Biosciences, Inc. filed the final prospectus for a registered offering.
3 Mar 2023securities registration● Neutral
Arcadia Biosciences, Inc. filed the final prospectus for a registered offering.
3 Mar 2023securities registration● Neutral
Arcadia Biosciences, Inc. filed the final prospectus for a registered offering.
14 Feb 2023substantial holder notice● Neutral
Armistice Capital, LLC, Steven Boyd disclosed a new substantial Arcadia Biosciences, Inc. shareholding (9.99% of votes).
2 Feb 2023director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Financial Officer Thomas J. Schaefer bought 700 shares on the open market at $0.23.
20 Jan 2023substantial holder notice● Neutral
Moral Compass Corporation, Terri Bishop, Peter Sperling, Darby Shupp, John G. Sperling reported a Arcadia Biosciences, Inc. shareholding of 1,125,769 shares (4.60% of votes) in a periodic institutional filing.
5 Jan 2023director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Financial Officer Thomas J. Schaefer received a stock option grant for 50,000 shares.
5 Jan 2023director interest notice● Neutral
Thomas J. Schaefer became a Arcadia Biosciences, Inc. Chief Financial Officer and company insider (initial ownership filing).
10 Nov 2022quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $1.6 million and a net loss of $2.9 million for the period ended 2022-09-30.
10 Nov 2022quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $1.6 million and a net loss of $2.9 million for the period ended 2022-09-30.
7 Oct 2022securities registration● Neutral
Arcadia Biosciences, Inc. filed the final prospectus for a registered offering.
27 Sept 2022securities registration● Neutral
Arcadia Biosciences, Inc. registered a securities offering with the SEC.